Preparation of Herbal Formulation for Inflammatory Bowel Disease Based on In Vitro Screening and In Vivo Evaluation in a Mouse Model of Experimental Colitis.
Animals
Anti-Inflammatory Agents
/ pharmacology
Colitis
/ drug therapy
Cytokines
/ metabolism
Dextran Sulfate
/ adverse effects
Disease Models, Animal
Drug Evaluation, Preclinical
/ methods
Epithelial Cells
/ metabolism
Female
Inflammatory Bowel Diseases
/ drug therapy
Mice
Monocytes
/ metabolism
Nitric Oxide
/ biosynthesis
Nitric Oxide Synthase
/ genetics
Plant Extracts
/ pharmacology
RAW 264.7 Cells
Tumor Necrosis Factor-alpha
/ metabolism
Aucklandia lappa
Terminalia chebula
Zingiber officinale
anti-inflammatory activity
inflammatory bowel disease
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
28 Jan 2019
28 Jan 2019
Historique:
received:
31
12
2018
revised:
19
01
2019
accepted:
25
01
2019
entrez:
31
1
2019
pubmed:
31
1
2019
medline:
2
5
2019
Statut:
epublish
Résumé
Many medicinal plants have been used traditionally in East Asia for the treatment of gastrointestinal disease and inflammation. The aim of this study was to evaluate the anti-inflammatory activity of 350 extracts (175 water extracts and 175 ethanol extracts) from 71 single plants, 97 mixtures of two plants, and seven formulations based on traditional medicine, to find herbal formulations to treat inflammatory bowel disease (IBD). In the in vitro screening, nitric oxide (NO), tumor necrosis factor (TNF)-α, and interleukin (IL)-6 levels were determined in LPS-treated RAW264.7 cells and the TNF-α induced monocyte-epithelial cell adhesion assay was used for the evaluation of the anti-inflammatory activity of the compounds. Dextran sulfate sodium (DSS)-induced colitis model and 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model were used to evaluate the therapeutic effect against IBD of the samples selected from the in vitro screening. KM1608, composed of
Identifiants
pubmed: 30696085
pii: molecules24030464
doi: 10.3390/molecules24030464
pmc: PMC6384830
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cytokines
0
Plant Extracts
0
Tumor Necrosis Factor-alpha
0
Nitric Oxide
31C4KY9ESH
Dextran Sulfate
9042-14-2
Nitric Oxide Synthase
EC 1.14.13.39
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Korea Institute for Advancement of Technology
ID : R0006060
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Planta Med. 1999 Mar;65(2):104-8
pubmed: 10193198
Immunology. 2004 Dec;113(4):427-37
pubmed: 15554920
Can J Gastroenterol. 2005 Sep;19(9):567-73
pubmed: 16151549
Lancet. 2007 May 12;369(9573):1627-40
pubmed: 17499605
Food Chem Toxicol. 2008 Feb;46(2):409-20
pubmed: 17950516
J Ethnopharmacol. 2008 Aug 13;118(3):367-72
pubmed: 18571884
Int Arch Allergy Immunol. 2010;151(2):98-106
pubmed: 19752563
Inflamm Bowel Dis. 2011 Jan;17(1):382-95
pubmed: 20645321
J Perianesth Nurs. 2010 Aug;25(4):214-20
pubmed: 20656257
PLoS One. 2011 Feb 23;6(2):e16999
pubmed: 21373195
Gut. 2011 May;60(5):571-607
pubmed: 21464096
J Ethnopharmacol. 2012 Jun 14;141(3):878-87
pubmed: 22521731
Inflammopharmacology. 2013 Oct;21(5):377-83
pubmed: 22956243
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27
pubmed: 26627550
J Ginseng Res. 2017 Jan;41(1):43-51
pubmed: 28123321
Bioorg Med Chem Lett. 2017 Jul 15;27(14):3076-3080
pubmed: 28554870
J Ginseng Res. 2017 Jul;41(3):257-267
pubmed: 28701865
Evid Based Complement Alternat Med. 2017;2017:8379843
pubmed: 28900464
Chin J Nat Med. 2018 Sep;16(9):683-692
pubmed: 30269845
Molecules. 2018 Oct 19;23(10):null
pubmed: 30347741